Trade-Ideas LLC identified




) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified uniQure as such a stock due to the following factors:

  • QURE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $5.2 million.
  • QURE has traded 403,343 shares today.
  • QURE is trading at 15.24 times the normal volume for the stock at this time of day.
  • QURE is trading at a new low 15.02% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in QURE with the Ticky from Trade-Ideas. See the FREE profile for QURE NOW at Trade-Ideas

More details on QURE:

uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. Currently there are 8 analysts that rate uniQure a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for uniQure has been 342,100 shares per day over the past 30 days. uniQure has a market cap of $489.9 million and is part of the health care sector and drugs industry. Shares are up 51.9% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates uniQure as a


. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

Highlights from the ratings report include:

  • AMSTERDAM MOLECULAR THERP's earnings per share declined by 42.9% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, AMSTERDAM MOLECULAR THERP reported poor results of -$2.55 versus -$0.56 in the prior year. For the next year, the market is expecting a contraction of 8.6% in earnings (-$2.77 versus -$2.55).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 76.4% when compared to the same quarter one year ago, falling from -$12.24 million to -$21.59 million.
  • Compared to other companies in the Biotechnology industry and the overall market, AMSTERDAM MOLECULAR THERP's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly increased by 886.81% to $43.80 million when compared to the same quarter last year. In addition, AMSTERDAM MOLECULAR THERP has also vastly surpassed the industry average cash flow growth rate of 1.02%.
  • Compared to its closing price of one year ago, QURE's share price has jumped by 72.56%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in QURE do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.